Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Smithkline Beecham (SBH) -- Ignore unavailable to you. Want to Upgrade?

To: NucTrader who wrote (44)	6/14/1998 5:51:00 PM
From: Henry Niman	Respond to of 61

SBH has a TZD in trials that should give WLA's Rezulin a real run for the money for treating and preventing type II diabetes. I am most familiar with their alliance with LGND which includes leptin and hematopoietic growth factors. They have discovered small molecules that should replace AMGN's blockbusters, Epogen and Neupogen, and the technology has VERY broad applications (but these products are at a relatively early stage of development - the growth factor mimics have not even started human trials yet.